Nicox Holds First Ophthalmology Scientific Advisory Board And Attends AAO 2013

Nicox S.A. (NYSE Euronext Paris: COX) today announced it has established a newScientific Advisory Board (SAB) with international Key Opinions Leaders (KOLs)in the ophthalmology field. The first SAB meeting will be held on November14, 2013 in New Orleans, Louisiana, United States, with the objective ofevaluating the existing data on second generation nitric oxide (NO)-donors anddiscussing their potential therapeutic use in certain ophthalmic disorders.Nicox's SAB will be led by Dr. Richard L. Lindstrom, founder and attendingsurgeon at Minnesota Eye Consultants and Adjunct Clinical Professor Emeritus atthe University of Minnesota Department of Ophthalmology. Dr. Lindstrom is aninternationally recognized leader in corneal, cataract, refractive and lasersurgery.AAO 2013Nicox will attend the 2013 Annual Meeting of the American Academy ofOphthalmology (AAO), taking place from November 16 to 18, 2013 in New Orleans,Louisiana, United States. Nicox can be found at booth number 4719. Nicox's USand European operational teams will attend the meeting, as well as severalmembers from the Executive team.About Dr. Richard L. LindstromDr Richard L. Lindstrom is Founder and attending surgeon at Minnesota EyeConsultants, Adjunct Clinical Professor Emeritus at the University of MinnesotaDepartment of Ophthalmology. He serves as Associate Director at the MinnesotaLions Eye Bank and as Board Member at the University of Minnesota Foundation. Heis also Visiting Professor at UC Irvine's Gavin Herbert Eye Institute and heserves on the Board of Directors of several publicly traded and privatecompanies and on a number of Journal editorial boards.Dr Lindstrom is a board-certified ophthalmologist and internationally recognizedleader in corneal, cataract, refractive and laser surgery. He has been at theforefront of ophthalmology's evolutionary changes throughout his career, as arecognized researcher, teacher, inventor, writer, lecturer and highly acclaimedphysician and surgeon. He holds over 38 patents in ophthalmology and hasdeveloped a number of solutions, intraocular lenses and instruments that areused in clinical practices globally....................................About NicoxNicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international companyfocused  on the ophthalmic  market. With a  heritage of innovative R&D, businessdevelopment  and commercial expertise, the Nicox  team is building a diversifiedportfolio  of therapies  and diagnostic  tools that  can help  people to enhancetheir  sight. The Company's commercial  portfolio and near-term pipeline alreadyinclude several innovative diagnostic tests intended for eye care professionals,as  well  as  a  range  of  eye  care products. Nicox's key proprietary asset inophthalmology  is  latanoprostene  bunod,  a  novel  compound  based  on Nicox'sproprietary  nitric  oxide  (NO)-donating  R&D  platform,  currently in Phase 3clinical  development  in  collaboration  with  Bausch  + Lomb for the potentialtreatment  of  glaucoma  and  ocular  hypertension.  Further NO-donors are underdevelopment, notably through partners.Nicox is headquartered in France, with research capabilities in Italy, a growingcommercial infrastructure in North America and in the major European markets andan  expanding international presence  through partners. Nicox  S.A. is listed onEuronext  Paris (Compartment B: Mid Caps). For  more information on Nicox or itsproducts please visit press release contains certain forward-looking statements. Although theCompany believes its expectations are based on reasonable assumptions, theseforward-looking statements are subject to numerous risks and uncertainties,which could cause actual results to differ materially from those anticipated inthe forward-looking statements.Risks factors which are likely to have a material effect on Nicox's business arepresented in the 4th chapter of the « Document de référence, rapport financierannuel et rapport de gestion 2012 » filed with the French Autorité des MarchésFinanciers (AMF) on March 22, 2013 and available on Nicox's website( and on the AMF's website ( Nicox Contact   Gavin Spencer | Executive Vice President Corporate Development                 Tel +33 (0)4 97 24 53 00 | Media Relations Europe          FTI Consulting                 Julia Phillips | D+44 (0)20 7269 7187 | M +44 (0) 7770 827 263                        Stephanie Cuthbert | D +44 (0)20 3077 0458 | M +44 (0)                 7843 080947                        Mo Noonan | D +44 (0)20 7269 7116 | M +44 (0)7876 444 977        United States   Pascale Communications                 Amy Phillips | M +1 412 327 9499                        Nicox holds first ophthalmology Scientific Advisory Board :[HUG#1739749]